Cypress Wealth Services LLC Sells 5,391 Shares of Pfizer Inc. (NYSE:PFE)

Cypress Wealth Services LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 24.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,666 shares of the biopharmaceutical company’s stock after selling 5,391 shares during the period. Cypress Wealth Services LLC’s holdings in Pfizer were worth $442,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Tallon Kerry Patrick purchased a new stake in Pfizer during the 4th quarter valued at approximately $509,000. Mirador Capital Partners LP raised its position in Pfizer by 4.5% during the fourth quarter. Mirador Capital Partners LP now owns 35,968 shares of the biopharmaceutical company’s stock valued at $954,000 after purchasing an additional 1,552 shares during the period. IFS Advisors LLC boosted its stake in Pfizer by 787.7% during the fourth quarter. IFS Advisors LLC now owns 3,693 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 3,277 shares during the period. Winch Advisory Services LLC grew its holdings in Pfizer by 6.5% during the 4th quarter. Winch Advisory Services LLC now owns 17,265 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 1,053 shares during the last quarter. Finally, Roble Belko & Company Inc lifted its position in shares of Pfizer by 49.7% during the fourth quarter. Roble Belko & Company Inc now owns 5,801 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 1,926 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $26.51 on Friday. The company has a market cap of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.64 and a beta of 0.64. The firm’s 50 day moving average is $26.11 and its two-hundred day moving average is $28.01. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter last year, the firm posted ($0.17) earnings per share. The business’s quarterly revenue was up 31.2% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 227.03%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Guggenheim cut their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Citigroup began coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.